arrow
C

Christopher J. Logothetis

The University of Texas MD Anderson Cancer Center
H指数:122
被引数:8.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cardiometabolic health’s influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer

心血管代谢健康对局部高危前列腺癌男性患者术前激素治疗效果的影响

2026-10-150
OAAI
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness

基于KLK3 SNP-SNP相互作用对的遗传风险评分预测前列腺癌侵袭性

2026-05-280
OAAI
Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment

骨转移性去势抵抗性前列腺癌的空间免疫谱分析揭示镭-223免疫调节骨-肿瘤微环境

2025-12-260
OAAI
PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression

PKA驱动的SPP1激活作为一种连接骨微环境与前列腺癌进展的新机制

2025-08-020
OA
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis

随机化Ⅱ期临床试验:针对出现淋巴结转移的前列腺癌患者,比较术前雄激素剥夺疗法联合或不联合Axitinib的治疗效果

2025-07-120
PRE
Body composition as a determinant of the therapeutic index with androgen signaling inhibition
2024-07-172
PRE
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates

阿帕鲁胺治疗中危前列腺癌的II期试验及其分子相关性

2024-06-041
PRE
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
2023-12-013
PRE
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

通过多祖先全基因组发现187种新的风险变异来表征前列腺癌风险

2023-11-0928
OA
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer
2023-07-296
OAAI
KDM4A promotes NEPC progression through regulation of MYC expression
2023-04-040
PRE